摘要
国内目前研究显示在初诊为前列腺癌的患者中转移性前列腺癌(mPC)患者大约占54%,其五年生存率相比非转移性前列腺癌低了两倍,同时mPC对药物耐药逐年增加,使优化其治疗选择彰显得更为重要。欧洲泌尿外科协会联合欧洲放射肿瘤学会、欧洲泌尿生殖放射学会与国际老年肿瘤学会(EAU-ESTRO-ESUR-SIOG)根据各大临床试验与基础研究每年制定了mPC的治疗指南,用于指导mPC的临床治疗及疾病监测,受到广大专家学者的广泛欢迎。因此,为了更好推广mPC的诊治指南,规范mPC的治疗,本文就2019年EAU-EANM-ESTRO-ESUR-SIOG指南中mPC的治疗更新、治疗检测、治疗时机进行解读。
Domestic studies have shown that metastatic prostate cancer(mPC)has a prevalence of approximately 54%in patients with first-stage prostate cancer,and its five-year survival rate is two times lower than non-metastatic cancer.The resistance of metastatic prostate cancer for existing drugs has increased year by year,which makes it critical to optimize treatment options.The European Journal of Urology,the European Society of Radiation Oncology,the European Society of Urogenital Radiology and the International Association of Geriatric Oncology(EAU-ESTRO-ESUR-SIOG),based on major clinical and basic experiments,develop annual guidelines for the treatment of mPC to guide the clinical treatments and disease monitoring,which enjoys tremendous popularity.Therefore,in order to better promote diagnosis and treatment guidelines and standardize treatment of mPC,this article will interpret the treatment update,treatment detection and treatment timing of mPC in the 2019 EAU-EANM-ESTRO-ESUR-SIOG guide.
作者
李晋
陈波
陈泽昱
曹德宏
柳良仁
魏强
董强
LI Jin;CHEN Bo;CHEN Zeyu;CAO Dehong;LIU Liangren;WEI Qiang;DONG Qiang(Department of Urology,West China Hospital,Sichuan University,Chengdu 610041,China;Research Institute of Urology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《西部医学》
2020年第2期160-165,共6页
Medical Journal of West China
关键词
转移性前列腺癌
一线治疗
内分泌治疗
指南
指南解读
Metastatic prostate cancer
First-line treatment
Androgen deprivation therapy
Guideline
Guideline interpretation
